Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to ...

Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $76 from $60 and keeps a Buy rating on the shares. The firm cites ...